Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in England.


Journal

JAMA neurology
ISSN: 2168-6157
Titre abrégé: JAMA Neurol
Pays: United States
ID NLM: 101589536

Informations de publication

Date de publication:
01 07 2020
Historique:
pubmed: 5 5 2020
medline: 18 2 2021
entrez: 5 5 2020
Statut: ppublish

Résumé

People with multiple sclerosis (MS) are associated with an increased risk of cardiovascular disease and mortality; however, evidence from population-based studies is sparse. To assess whether the risk of macrovascular events and mortality differs among people with MS compared with a matched population without MS in England. A population-based retrospective matched cohort study was conducted in general practices registered with the Clinical Practice Research Datalink in England between January 1, 1987, and September 30, 2018, with a mean (SD) follow-up of 11.3 (6.5) years. A total of 12 251 patients with MS were matched with up to 6 people without MS (n = 72 572) by age, sex, and general practice. People with 3 or more diagnoses of MS recorded during the study period were included. The first MS diagnosis was considered as index date. Multiple sclerosis status. Analyses were also stratified by sex. Main outcomes were acute coronary syndrome, cerebrovascular disease, any macrovascular disease (including peripheral arterial disease), and mortality (all-cause mortality and cardiovascular disease-specific mortality). Cox proportional hazards regression and Fine and Gray proportional subhazard regression models were used to assess differences in rates. A total of 12 251 people with MS (66.9% women; mean [SD] age, 44.9 [13.3] years) were matched with 72 572 people without MS (69.8% women; mean [SD] age, 44.9 [13.3] years). As compared with people without MS, people with MS were associated with a 28% increased hazard of acute coronary syndrome (hazard ratio [HR], 1.28; 95% CI, 1.09-1.51), 59% increased hazard of cerebrovascular disease (HR, 1.59; 95% CI, 1.32-1.92), 32% increased hazard of any macrovascular disease (HR, 1.32; 95% CI, 1.15-1.52), 3.5-fold increased hazard of all-cause mortality (HR, 3.46; 95% CI, 3.28-3.65), and 1.5-fold increased hazard in cardiovascular disease mortality (HR, 1.47; 95% CI, 1.27-1.71). Differences in macrovascular events were more pronounced among women than men. Mortality risk was also higher for women than men. Treatment with lipid-lowering medications (mainly statins) was associated with lower mortality rates among people with MS. This study suggests that MS is associated with an increased risk of cardiovascular and cerebrovascular disease that is not completely accounted for by traditional vascular risk factors. Given the adverse effects of these comorbidities on outcomes in patients with MS, further investigation is needed.

Identifiants

pubmed: 32364569
pii: 2765472
doi: 10.1001/jamaneurol.2020.0664
pmc: PMC7199174
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

820-828

Références

Lancet. 2014 Jun 28;383(9936):2213-21
pubmed: 24655729
Sci Rep. 2018 Feb 19;8(1):3300
pubmed: 29459794
Mult Scler. 2015 Mar;21(3):318-31
pubmed: 25533300
BMJ. 2012 Aug 30;345:e5567
pubmed: 22936794
JAMA. 2006 Oct 11;296(14):1735-41
pubmed: 17032986
Restor Neurol Neurosci. 2006;24(2):79-95
pubmed: 16720944
Stat Sci. 2010 Feb 1;25(1):1-21
pubmed: 20871802
Lancet. 2017 Dec 16;390(10113):2643-2654
pubmed: 28943267
Sci Rep. 2020 Jan 27;10(1):1231
pubmed: 31988330
Mult Scler Relat Disord. 2014 Jan;3(1):72-7
pubmed: 25877976
Lancet. 2004 Sep 11-17;364(9438):937-52
pubmed: 15364185
Arthritis Rheum. 2005 Mar;52(3):722-32
pubmed: 15751097
Int J Clin Pract. 2008 Aug;62(8):1246-54
pubmed: 18564201
Eur J Neurol. 2008 Jun;15(6):579-83
pubmed: 18474075
BMJ. 2018 May 23;361:k1786
pubmed: 29792314
Neuroepidemiology. 2008;30(4):234-8
pubmed: 18437030
Mult Scler. 2013 Sep;19(10):1336-40
pubmed: 23364857
JAMA. 2013 Jan 2;309(1):71-82
pubmed: 23280227
Prev Med. 2015 Sep;78:1-8
pubmed: 26051202
Neuroepidemiology. 2010;35(4):267-74
pubmed: 20881430
J Public Health (Oxf). 2014 Dec;36(4):684-92
pubmed: 24323951
J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):61-6
pubmed: 21865212
Neurology. 2019 Apr 2;92(14):e1624-e1633
pubmed: 30842298
CMAJ. 2016 Oct 4;188(14):E342-E351
pubmed: 27455981
Prog Neurobiol. 2009 May;88(1):64-75
pubmed: 19428962
Brain Imaging Behav. 2008 Jun 1;2(2):94
pubmed: 20157644
J Neurol. 2019 May;266(5):1095-1106
pubmed: 30778708
Neurol Clin Pract. 2016 Oct;6(5):397-408
pubmed: 27847682
Expert Rev Neurother. 2013 Dec;13(12 Suppl):3-9
pubmed: 24289836
Mult Scler. 2013 Sep;19(10):1323-9
pubmed: 23549432
J Cereb Blood Flow Metab. 2012 Nov;32(11):1973-6
pubmed: 22929438
Arthritis Rheum. 2001 Dec;44(12):2737-45
pubmed: 11762933
Ann Neurol. 2001 Jul;50(1):121-7
pubmed: 11456302
J Innov Health Inform. 2017 Oct 17;24(3):942
pubmed: 29121851
Neurology. 2019 Mar 5;92(10):e1016-e1028
pubmed: 30770432
Neurology. 2016 Apr 5;86(14):1279-1286
pubmed: 26962066
J Epidemiol Community Health. 2019 Jan;73(1):11-18
pubmed: 30282645
BMJ. 2017 Nov 20;359:j5019
pubmed: 29158232
Ann Neurol. 2018 Jun;83(6):1162-1173
pubmed: 29740872
Neurology. 2013 Feb 5;80(6):548-52
pubmed: 23365063
Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8880-5
pubmed: 9671773
J Clin Invest. 1997 Dec 1;100(11):2671-9
pubmed: 9389730
Nat Rev Neurol. 2017 Jun;13(6):375-382
pubmed: 28303911
Can J Cardiol. 2011 Mar-Apr;27(2):174-82
pubmed: 21459266
Neurology. 2015 Jul 21;85(3):240-7
pubmed: 26019190
Eur J Neurol. 2012 Apr;19(4):616-24
pubmed: 22117611
Brain. 2004 Apr;127(Pt 4):844-50
pubmed: 14960501
CMAJ. 2016 Jul 12;188(10):E228-E238
pubmed: 27141033

Auteurs

Raffaele Palladino (R)

Department of Primary Care and Public Health, School of Public Health, Imperial College of London, London, United Kingdom.
Department of Public Health, Federico II University, Naples, Italy.

Ruth Ann Marrie (RA)

Department of Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Department of Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.

Azeem Majeed (A)

Department of Primary Care and Public Health, School of Public Health, Imperial College of London, London, United Kingdom.

Jeremy Chataway (J)

Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, United Kingdom.
National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH